Distribution of Model Predicted Relatlimab Exposures (Cavg1 and Cavgss) at 160 mg Q4W by ADA Status
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: